Dossier assessment

Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-45
Last updated

Report documents

  1. Extract of dossier assessment

    Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 681 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-45_en
  2. Dossier assessment

    Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-45

Dossier assessment

Indication:

Adult patients with advanced clear cell renal cell carcinoma that has progressed following 2 or more lines of therapy that included a PD‑(L)1 inhibitor and at least 2 vascular endothelial growth factor‑targeted therapies

Result of dossier assessment:
  • Patients < 65 years of age for whom everolimus is a suitable individualized treatment: hint of a minor added benefit
  • Patients ≥ 65 years of age for whom everolimus is a suitable individualized treatment: hint of a considerable added benefit
  • Patients for whom everolimus is not a suitable individualized treatment: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2025-09-18 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A25-45
Commission
Commission awarded on 28.03.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-45_en

Connected Projects

  1. Dossier assessment

    Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-44
    Last updated

    Status: Commission completed

  2. Addendum

    Belzutifan (renal cell carcinoma) – Addendum to Project A25-45

    Project no.
    A25-107
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form